Business
M2Bio Sciences Chair, Prof Maharaj, to Deliver Keynote Address on Cutting-Edge Biotechnology Advancements
M2Bio Sciences Chair, Prof Maharaj, to Deliver Keynote Address on Cutting-Edge Biotechnology Advancements.
About this update from Institute Of Biomedical Research Corp.
[{"type":"text","content":"CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / October 2, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update: M2Bio Sciences is delighted to announce that Professor Vinesh Maharaj will be a keynote speaker at the 13th Annual Biomedical Research & Innovation Platform Symposium on the 16th & 17th of October 2023. This event promises to be an electrifying exploration of innovation, tradition, and groundbreaking potential in biomedicine. It will feature a dynamic lineup of speakers and networking opportunities, providing an immersive experience for those keen to explore the latest trends, innovations, and investment prospects in the biomedical field.Prof. Maharaj is the Deputy Dean of Research and Postgraduate Education at the University of Pretoria and the chair of the M2Bio-Discovery Centre for AI-Driven Phytomedicine Research. He will cover "African Traditional Medicine: Past, Present, and Future Perspectives". His keynote address will delve into the historical roots of traditional healing practices, showcase present-day innovations, and provide a tantalizing glimpse into the limitless potential for the future. Professor Maharaj's visionary perspective on AI-driven phytomedicine research will undoubtedly stimulate the imagination of investors seeking groundbreaking opportunities in the biotech sector.African Ginger (Siphonochilus aethiopicus) will feature as part of Prof Maharaj's presentation, one of the leading research projects for M2Bio Sciences. Respiratory viral diseases, including COVID-19 and influenza, threaten global health, societal function, and the world's economy. Despite the numerous vaccines and remedies currently available for its treatment, seasonal flu is estimated to cause about 3 to 5 million cases of severe illness and about 290,000 to 650,000 respiratory fatalities annually globally[1]. Consequently, there remains an urgent need for the discovery and development of a cheaper, more efficacious treatment regimen that ideally has dual activity against these respiratory viral diseases, likely to occur as co-infections[...